IDD Biotech, headquartered in Lyon, France, is a biotechnology company focused on the research and development of monoclonal antibodies (MAbs) for oncology and hematology indications. Established in 2008, IDD has built a differentiated portfolio of therapeutic MAbs, several of which have been licensed to global pharmaceutical and biotech companies.

Enzene Biosciences, a subsidiary of Alkem Laboratories, is an innovation-driven biopharmaceutical company based in Pune, India. Enzene has developed a Continuous Manufacturing Platform for biologics and operates a fully automated, cGMP-compliant facility designed to disrupt the affordability and scalability of biotech products globally.

IDD Biotech engaged Novistra Capital to advise on a strategic licensing transaction for its leading oncology asset—a CD19-targeting monoclonal antibody with “best-in-class” potential. Novistra led the deal structuring and negotiations, identifying Enzene as an ideal partner with complementary manufacturing capabilities and a strong innovation platform.

The transaction was designed to provide IDD with a capital-efficient path to clinical development through an exclusive licensing agreement with Enzene for phases 1, 2, and 3 manufacturing.

IDD Biotech entered into an exclusive license agreement with Enzene Biosciences, granting rights to manufacture clinical batches of its CD19 asset at Enzene’s cGMP-compliant facility in India. The agreement enables accelerated development of IDD’s antibody pipeline, while leveraging Enzene’s advanced manufacturing capabilities to optimise cost and scale.

This transaction reflects Novistra’s cross-border execution capability in biotech and life sciences, and its ability to align early-stage innovation with strategic industrial partners in high-growth markets.